![Quiver Logo](/static/img/logo-icon.png)
![SYRE logo](https://quiver-logos.s3.us-east-2.amazonaws.com/syre.png)
Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SYRE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of SYRE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SYRE's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to SYRE
Recent picks made for SYRE stock on CNBC
ETFs with the largest estimated holdings in SYRE
Flights by private jets registered to SYRE
![Quiver Logo](/static/img/logo-icon.png)